The COVID-19 Clinical Neuroscience Study (COVID-CNS)

COVID-19患者在感染期间经常出现脑部问题，并可能留下脑损伤的症状。类似的问题在以前的大流行中也曾出现过，包括100多年前的西班牙流感，但人们对这种情况是如何发生的以及为什么会发生还知之甚少。我们已经接到通知，有800名英国患者因COVID-19而出现了这些并发症。我们有一个独特的机会来了解这些问题是如何发生的，并制定预防和治疗这些问题的战略。我们将提出的问题包括COVID-19对谁造成伤害？它是通过侵入大脑来做到这一点的吗？还是通过引发过度的免疫反应或干扰神经组织的血液供应？我们将通过对这800例患者和500例对照患者进行深入的临床、实验室和影像学研究来回答这些问题（在大流行期间因COVID-19 [400]或非COVID-19 [100]而住院）。没有这种理解，我们无法确定抗病毒药物或调节免疫系统或改善血液供应的治疗是否会有所帮助，我们将通过我们的世界卫生组织委托的工作组（共同主席Michael）应用这种理解来制定临床护理指南，为有针对性的临床试验确定患者，并最终改善患者的结果。我们将同意所有参与者使用NIHR BioResource，将COVID-CNS建立为试验准备队列，并确保其他研究人员获得数据和样本。COVID-CNS由联合PI Benedict Michael和Gerome Breen共同领导

COVID-19 patients frequently suffer brain problems during the infection and can be left with symptoms of brain injury. Similar problems have been seen in previous pandemics, including Spanish influenza over 100 years ago, but how and why this occurs is poorly understood.We have already been notified of 800 UK patients with these complications due to COVID-19. We have a unique opportunity to understand how these problems occur and develop strategies to prevent and treat them. The questions we will ask include in whom does COVID-19 cause injury? Does it do this by invading the brain? Or by triggering excessive immune responses or interfering with the blood supply to nervous tissue?We will answer these questions through in depth clinical, laboratory, and imaging studies of these 800 patients in comparison to 500 control patients (hospitalised during the pandemic with COVID-19 [400] or without COVID-19 [100]).Without this understanding, we cannot determine whether anti-viral medication, or treatments that modulate the immune system or that improve blood supply will help, and if so in which patients.We will apply this understanding through our World Health Organisation-commissioned Task Force (co-Chair Michael) to develop clinical care guidelines, identify patients for targeted clinical trials, and ultimately improve patient outcomes.We will consent all participants to the NIHR BioResource, establishing COVID-CNS as a trial ready cohort and ensuring data and sample access for other researchers.N.B. COVID-CNS is jointly led by co-PIs Benedict Michael and Gerome Breen